Healthcare
Stryker Corporation(SYK)
Live Price
Offline$312.20
+2.15% today
1Y Change
-16.87%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $112.88B
- Revenue Growth
- +11.2%
- EPS Growth
- +8.0%
- Dividend Yield
- 1.2%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stryker Corporation (SYK) is a Healthcare stock with a market cap of $112.88B and listed on NYSE. The stock last traded around $312.20 and down 16.9% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +11.2%, EPS growth of +8.0%, a dividend yield of 1.2%. What stands out right now is revenue +11.2%, EPS +8.0%, free cash flow +22.8% with operating margin 21.3% and ROIC 9.8%. The dividend is present but secondary, with a yield around 1.2%. Valuation already assumes a fairly strong business story at P/E 33.8 and price/sales 4.5. Stock Foundry combines SYK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.2% vs +7.6% peer median
Operating Margin
Near sector median
+21.3% vs +19.4% peer median
P/E
Below sector median
33.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.2% and EPS at +8.0%, with operating margin around 21.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | -6.5% | -6.6% | -3.2% |
2026 Jan 29, 2026 | +1.6% | +4.3% | +2.3% | +9.4% |
2025 Oct 30, 2025 | +1.9% | -3.5% | -4.1% | +0.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SYK Max Drawdown
-29.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYK and SPY.
Company Overview
Stryker Corporation
New York Stock Exchange
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
- Leadership
- Kevin A. Lobo
- IPO Date
- Mar 17, 1980
- Employees
- 53.0k
- Street Address
- 1941 Stryker Way
- Mailing
- Portage, MI, 49002
- Region
- Portage, MI, US
- Reporting Currency
- USD
- Investor Line
- 269 385 2600
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 33.8
- EV/EBITDA
- 22.7
- Price/Sales
- 4.5
- Price/Book
- 5.1
Growth
- Revenue
- +11.2%
- EPS
- +8.0%
- Free Cash Flow
- +22.8%
Profitability
- Gross Margin
- 63.7%
- Operating Margin
- 21.3%
- Net Margin
- 13.2%
- ROE
- 15.2%
- ROIC
- 9.8%
Balance Sheet
- Debt/Equity
- 0.64
- Current Ratio
- 2.11
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.